Featured News
452Wire StoriesAsia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity” report has...
- 371Wire Stories
Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity” report has...
- 415Wire Stories
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO–(BUSINESS WIRE)–Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in...
- 457Wire Stories
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO–(BUSINESS WIRE)–Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in...
- 438Wire Stories
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO–(BUSINESS WIRE)–Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in...
- 444Wire Stories
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China–(BUSINESS WIRE)–#ADC–Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical...
- 401Wire Stories
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China–(BUSINESS WIRE)–#ADC–Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical...
- 485Wire Stories
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China–(BUSINESS WIRE)–#ADC–Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical...
- 457Wire Stories
Biocytogen Announces RenLite™ Licensing Agreement with Janssen
BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc.,...
- 442Wire Stories
Biocytogen Announces RenLite™ Licensing Agreement with Janssen
BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc.,...
- 445Wire Stories
Biocytogen Announces RenLite™ Licensing Agreement with Janssen
BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc.,...
